PMID- 36761740 OWN - NLM STAT- MEDLINE DCOM- 20230213 LR - 20230327 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 14 DP - 2023 TI - Safety of SARS-CoV2 vaccination and COVID-19 short-term outcome in pediatric acquired demyelinating disorders of central nervous system: A single center experience. PG - 1106472 LID - 10.3389/fimmu.2023.1106472 [doi] LID - 1106472 AB - INTRODUCTION: Concern of a correlation between disease relapse in patients with acquired demyelinating disorders of central nervous system (CNS) and SARS-CoV2 vaccines has been raised. In this single center study, we retrospectively evaluated safety of SARS-CoV2 vaccination and COVID-19 short-term outcome in pediatric acquired demyelinating disorders of CNS. MATERIALS AND METHODS: Patients with multiple sclerosis (MS), myelin oligodendrocyte glycoprotein antibody associated disease (MOGAD) and neuromyelitis optica spectrum disorder (NMOSD) with disease onset before 18 years of age were included. Demographic and clinical data, and information regarding previous SARS-CoV-2 infection and vaccination were collected. RESULTS: We included nine patients with MOGAD. Six patients received SARS-CoV2 vaccination and complained pain at injection site while only one had fever and fatigue. Median follow-up was 28 weeks (range 20-48). Seven patients had COVID-19 occurring with mild flu-like symptoms and median follow-up was 28 weeks (range 24-34). Nobody had disease relapse. Five patients with NMOSD were included. All patients received SARS-CoV2 vaccination (BNT162b2-Pfizer-BioNTech). The median follow-up was 20 weeks (range 14-24) and only two patients complained pain at injection site, fever and fatigue. Three patients had also COVID-19 with mild flu-like symptoms, despite two of them being under immunosuppressive treatment. Lastly, forty-three patients with MS were included. 35 out of 43 received SARS-CoV2 vaccination with a median follow-up of 24 weeks (range 8-36). Fourteen patients had no side effects, while 21 complained mild side effects (mainly pain at injection site) and one experienced a disease relapse with complete recovery after steroid therapy. At vaccination, all but one were under treatment. Sixteen patients had COVID-19 occurring with mild symptoms. DISCUSSION: COVID-19 outcome was good although many patients were under immunosuppressive treatment. Vaccine-related side effects were frequent but were mild and self-limited. Only one MS patient had a post-vaccination relapse with complete recovery after steroid therapy. In conclusion, our data support the safety of SARS-CoV-2 vaccines in pediatric MS, MOGAD and NMOSD. CI - Copyright (c) 2023 Monte, Papetti, Ferilli, Ursitti, Moavero, Sforza, Panella, Tarantino, Checchi, Vigevano, Palma and Valeriani. FAU - Monte, Gabriele AU - Monte G AD - Developmental Neurology Unit, Bambino Gesu Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy. FAU - Papetti, Laura AU - Papetti L AD - Developmental Neurology Unit, Bambino Gesu Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy. FAU - Ferilli, Michela Ada Noris AU - Ferilli MAN AD - Developmental Neurology Unit, Bambino Gesu Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy. FAU - Ursitti, Fabiana AU - Ursitti F AD - Developmental Neurology Unit, Bambino Gesu Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy. FAU - Moavero, Romina AU - Moavero R AD - Developmental Neurology Unit, Bambino Gesu Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy. AD - Child Neurology and Psychiatry Unit, Department of System Medicine, Tor Vergata University of Rome, Rome, Italy. FAU - Sforza, Giorgia AU - Sforza G AD - Developmental Neurology Unit, Bambino Gesu Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy. FAU - Panella, Elena AU - Panella E AD - Child Neurology and Psychiatry Unit, Department of System Medicine, Tor Vergata University of Rome, Rome, Italy. FAU - Tarantino, Samuela AU - Tarantino S AD - Developmental Neurology Unit, Bambino Gesu Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy. FAU - Checchi, Martina Proietti AU - Checchi MP AD - Developmental Neurology Unit, Bambino Gesu Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy. FAU - Vigevano, Federico AU - Vigevano F AD - Developmental Neurology Unit, Bambino Gesu Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy. FAU - Palma, Paolo AU - Palma P AD - Clinical Immunology and Vaccinology Unit, Bambino Gesu Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy. AD - Chair of Pediatrics, Department of Systems Medicine, Tor Vergata University of Rome, Rome, Italy. FAU - Valeriani, Massimiliano AU - Valeriani M AD - Developmental Neurology Unit, Bambino Gesu Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy. AD - Center for Sensory-Motor Interaction, Aalborg University, Denmark, Neurology Unit, Aalborg, Denmark. LA - eng PT - Journal Article DEP - 20230125 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (BNT162 Vaccine) RN - 0 (COVID-19 Vaccines) RN - 0 (Immunosuppressive Agents) RN - 0 (RNA, Viral) RN - 0 (Steroids) SB - IM MH - Humans MH - BNT162 Vaccine MH - *COVID-19/prevention & control MH - *COVID-19 Vaccines/adverse effects/therapeutic use MH - *Drug-Related Side Effects and Adverse Reactions MH - Fatigue MH - Fever MH - Immunosuppressive Agents MH - *Multiple Sclerosis MH - *Neuromyelitis Optica MH - Pain MH - Retrospective Studies MH - RNA, Viral MH - SARS-CoV-2 MH - Steroids MH - Vaccination/adverse effects MH - Demyelinating Diseases PMC - PMC9905148 OTO - NOTNLM OT - COVID-19 vaccination OT - MOGAD OT - NMOSD OT - SARS-CoV2 OT - multiple sclerosis OT - safety COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor DL declared a shared parent affiliation with some of the authors RM, PP at the time of review. EDAT- 2023/02/11 06:00 MHDA- 2023/02/14 06:00 PMCR- 2023/01/25 CRDT- 2023/02/10 03:12 PHST- 2022/11/23 00:00 [received] PHST- 2023/01/11 00:00 [accepted] PHST- 2023/02/10 03:12 [entrez] PHST- 2023/02/11 06:00 [pubmed] PHST- 2023/02/14 06:00 [medline] PHST- 2023/01/25 00:00 [pmc-release] AID - 10.3389/fimmu.2023.1106472 [doi] PST - epublish SO - Front Immunol. 2023 Jan 25;14:1106472. doi: 10.3389/fimmu.2023.1106472. eCollection 2023.